The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial
Open accessAbstract
CONTEXT: Sentinel lymph node dissection (SLND) accurately identifies nodal metastasis of early breast cancer, but it is not clear whether further nodal dissection affects survival. OBJECTIVE: To determine the effects of complete axillary lymph node dissection (ALND) on survival of patients with sentinel lymph node (SLN) metastasis of breast cancer. DESIGN, SETTING, AND PATIENTS: The American College of Surgeons Oncology Group Z0011 trial, a phase 3 noninferiority trial conducted at 115 sites and enrolling patients from May 1999 to December 2004. Patients were women with clinical T1-T2 invasive breast cancer, no palpable adenopathy, and 1 to 2 SLNs containing metastases identified by frozen section, touch preparation, or hematoxylin-eosin staining on permanent section. Targeted enrollment was 1900 women with final analysis after 500 deaths, but the trial closed early because mortality rate was lower than expected. INTERVENTIONS: All patients underwent lumpectomy and tangential whole-breast irradiation. Those with SLN metastases identified by SLND were randomized to undergo ALND or no further axillary treatment. Those randomized to ALND underwent dissection of 10 or more nodes. Systemic therapy was at the discretion of the treating physician. MAIN OUTCOME MEASURES: Overall survival was the primary end point, with a noninferiority margin of a 1-sided hazard ratio of less than 1.3 indicating that SLND alone is noninferior to ALND. Disease-free survival was a secondary end point. RESULTS: Clinical and tumor characteristics were similar between 445 patients randomized to ALND and 446 randomized to SLND alone. However, the median number of nodes removed was 17 with ALND and 2 with SLND alone. At a median follow-up of 6.3 years (last follow-up, March 4, 2010), 5-year overall survival was 91.8% (95% confidence interval [CI], 89.1%-94.5%) with ALND and 92.5% (95% CI, 90.0%-95.1%) with SLND alone; 5-year disease-free survival was 82.2% (95% CI, 78.3%-86.3%) with ALND and 83.9% (95% CI, 80.2%-87.9%) with SLND alone. The hazard ratio for treatment-related overall survival was 0.79 (90% CI, 0.56-1.11) without adjustment and 0.87 (90% CI, 0.62-1.23) after adjusting for age and adjuvant therapy. CONCLUSION: Among patients with limited SLN metastatic breast cancer treated with breast conservation and systemic therapy, the use of SLND alone compared with ALND did not result in inferior survival. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00003855.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., Jeong, J.-H., & Wolmark, N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa022152 · Cited by 6,249
The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited
Fidler, I. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1098 · Cited by 4,686
Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., Aguilar, M., & Marubini, E. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020989 · Cited by 4,450
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer
Veronesi, U., Paganelli, G., Viale, G., Luini, A., Zurrida, S., Galimberti, V., Intra, M., Veronesi, P., Robertson, C., Maisonneuve, P., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa012782 · Cited by 2,210
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,182
Krag, D. N., Anderson, S. J., Julian, T. B., Brown, A. M., Harlow, S. P., Costantino, J. P., Ashikaga, T., Weaver, D. L., Mamounas, E. P., Jalovec, L. M., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70207-2 · Cited by 1,920
Lyman, G. H., Giuliano, A. E., Somerfield, M. R., Benson, A. B., Bodurka, D. C., Burstein, H. J., Cochran, A. J., Cody, H. S., Edge, S. B., Galper, S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.001 · Cited by 1,887
Self-citationFisher, B., Redmond, C., Poisson, R., Margolese, R., Wolmark, N., Wickerham, L., Fisher, E., Deutsch, M., Caplan, R., Pilch, Y., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198903303201302 · Cited by 1,587
Albain, K. S., Barlow, W. E., Shak, S., Hortobagyi, G. N., Livingston, R. B., Yeh, I.-T., Ravdin, P., Bugarini, R., Baehner, F. L., Davidson, N. E., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70314-6 · Cited by 1,407
Fisher, B., Jeong, J.-H., Anderson, S., Bryant, J., Fisher, E. R., & Wolmark, N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020128 · Cited by 1,400
Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp322 · Cited by 1,374
Giuliano, A. E., McCall, L., Beitsch, P., Whitworth, P. W., Blumencranz, P., Leitch, A. M., Saha, S., Hunt, K. K., Morrow, M., & Ballman, K. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181f08f32 · Cited by 1,263
Self-citationEarly Breast Cancer Trialists’ Collaborative Group, & Peto, R. (1993) · Recent Results in Cancer Research · doi:10.1007/978-3-642-84745-5_21 · Cited by 958
Lucci, A., McCall, L. M., Beitsch, P. D., Whitworth, P. W., Reintgen, D. S., Blumencranz, P. W., Leitch, A. M., Saha, S., Hunt, K. K., & Giuliano, A. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.4062 · Cited by 920
Self-citationMeeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Goldhirsch, A., Wood, W. C., Senn, H.-J., Glick, J. H., & Gelber, R. D. (1995) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/87.19.1441 · Cited by 689
Sentinel Lymph Node Biopsy in Breast Cancer: Ten-Year Results of a Randomized Controlled Study
Veronesi, U., Viale, G., Paganelli, G., Zurrida, S., Luini, A., Galimberti, V., Veronesi, P., Intra, M., Maisonneuve, P., Zucca, F., et al. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181c0e92a · Cited by 551
Assessment of morbidity from complete axillary dissection
Ivens, D., Hoe, A., Podd, T., Hamilton, C., Taylor, I., & Royle, G. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.230 · Cited by 522
山口, 博. (2006) · Mebio oncology · Cited by 516
Fleissig, A., Fallowfield, L. J., Langridge, C. I., Johnson, L., Newcombe, R. G., Dixon, J. M., Kissin, M., & Mansel, R. E. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9025-7 · Cited by 494
Cm, R., Zahrieh, D., Forbes, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5784 · Cited by 408
Orr, R. K. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0109-1 · Cited by 343
Rubinstein, L. V., Gail, M. H., & Santner, T. J. (1981) · Journal of Chronic Diseases · doi:10.1016/0021-9681(81)90007-2 · Cited by 267
Coutant, C., Olivier, C., Lambaudie, E., Fondrinier, E., Marchal, F., Guillemin, F., Seince, N., Thomas, V., Levêque, J., Barranger, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7418 · Cited by 259
Martelli, G., Boracchi, P., De Palo, M., Pilotti, S., Oriana, S., Zucali, R., Daidone, M. G., & De Palo, G. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000167759.15670.14 · Cited by 200
Martelli, G., Miceli, R., Daidone, M. G., Vetrella, G., Cerrotta, A. M., Piromalli, D., & Agresti, R. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1217-7 · Cited by 175
Early Versus Delayed Shoulder Motion Following Axillary Dissection: A Randomized Prospective Study
Lotze, M. T., DUNCAN, M. A., Gerber, L. H., Woltering, E. A., & Rosenberg, S. A. (1981) · Annals of Surgery · doi:10.1097/00000658-198103000-00007 · Cited by 121
Primary Breast Cancer Complications of Axillary Management
Yeoh, E. K., Denham, J. W., Davies, S., & Spittle, M. F. (1986) · Acta Radiologica Oncology · doi:10.3109/02841868609136386 · Cited by 86
van la Parra, R. F. D., Ernst, M. F., Bevilacqua, J. L. B., Mol, S. J. J., Zee, K. J. V., Broekman, J. M., & Bosscha, K. P. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0359-y · Cited by 72
Adjuvant therapy for breast cancer — results from the USA consensus conference
Abrams, J. S. (2001) · Breast Cancer · doi:10.1007/bf02967528 · Cited by 68
Kaji, A. H., & Lewis, R. J. (2010) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2010.01.024 · Cited by 14
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Breast Cancer Treatment: A Review
Waks, A. G., & Winer, E. P. (2019) · JAMA · doi:10.1001/jama.2018.19323 · Cited by 4,804
Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Nomograms in oncology: more than meets the eye
Balachandran, V. P., Gonen, M., Smith, J. J., & DeMatteo, R. P. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71116-7 · Cited by 3,292
Metadata
- Authors
- Giuliano, A. E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-02-09
- Volume
- 305
- Issue
- 6
- Pages
- 569
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2096785769
- Cited by
- 2,942
- References
- 35
- FWCI
- 89.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.